The patent protects NextCell’s methodology for predicting the efficacy of mesenchymal stromal cell (MSC) therapy in individual patients, as well as the approach for determining personalized treatment options based on that prediction.

The patent further reinforces NextCell’s expanding portfolio of intellectual property, covering essential technologies for the production and use of MSC-based therapies in autoimmune and inflammatory diseases, it states. The MSC Prediction Algorithm patent was granted by the USPTO on 15th April 2025. It covers the development of an algorithm to assess the in vitro (laboratory-based) efficacy of MSC therapy as a predictor of clinical effectiveness for specific patients with conditions such as type 1 diabetes. The patent also includes claims for methods to personalized treatment plans based on the evaluation of laboratory results.

“As we move closer to commercialising ProTrans, our growing patent portfolio enhances our value and appeal to potential partners while protecting our proprietary technology,” says Mathias Svahn, CEO of NextCell. “These patents underscore the uniqueness of our product, development processes and manufacturing methods – innovations that are key to entering global markets.”